Iobenguane i-131 - Generic Drug Details

What are the generic sources for iobenguane i-131 and what is the scope of freedom to operate?

Iobenguane i-131 is the generic ingredient in one branded drug marketed by Progenics Pharms Inc and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for iobenguane i-131

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	12
Clinical Trials:	16
Patent Applications:	180
What excipients (inactive ingredients) are in iobenguane i-131?	iobenguane i-131 excipients list
DailyMed Link:	iobenguane i-131 at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for iobenguane i-131

Constraining patent/regulatory exclusivity:

TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER WITH IOBENGUANE SCAN POSITIVE, UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC PHEOCHROMOCYTOMA OR PARAGANGLIOMA WHO REQUIRE SYSTEMIC ANTICANCER THERAPY

Dosage:

SOLUTION;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for iobenguane i-131

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Jubilant DraxImage Inc.	Phase 2
Mayo Clinic	Early Phase 1
National Cancer Institute (NCI)	Early Phase 1

See all iobenguane i-131 clinical trials

US Patents and Regulatory Information for iobenguane i-131

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Progenics Pharms Inc	AZEDRA	iobenguane i-131	SOLUTION;INTRAVENOUS	209607-001	Jul 30, 2018		DISCN	Yes	No